BioSpace News Archive

Drug Development

Merck’s Recarbrio Shows Success in Late-Stage Trial for HABP/VABP Patients

Nicholas Kartsonis, head of clinical research in infectious diseases and vaccines at Merck Research Laboratories, noted that additional treatment options are needed for critically ill patients with respiratory infections.

September 30, 2019
·
2 min read
·
Alex Keown
Biotech Bay

Dana-Farber Study Confirms Accuracy of GRAIL’s Blood Test for Cancer

A new blood test in development from GRAIL, Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.

September 30, 2019
·
2 min read
·
Alex Keown
Policy

What Do the J&J and Purdue Pharma Outcomes Mean to the Pharma Industry?

Oklahoma was the first state to file suit against opioid manufacturers. The success of their legal strategy will have a significant impact on the opioid–and pharmaceutical–industry going forward.

September 30, 2019
·
5 min read
·
Gina Hagler
Deals

Gene-Editing Company Beam Seeks $100 Million IPO

Beam, which is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019, filed its IPO plans with the U.S. Securities and Exchange Commission on Friday.

September 30, 2019
·
2 min read
·
Alex Keown
Drug Development

ESMO: Keytruda Flexes Muscle in Early-Stage Triple-Negative Breast Cancer

Merck’s vaunted checkpoint inhibitor Keytruda combined with chemotherapy proved to be more efficacious than chemotherapy alone as neoadjuvant therapy in pre- and post-surgery triple-negative breast cancer patients.

September 30, 2019
·
2 min read
·
Alex Keown
Using Fruit Flies to Personalize Cancer Treatment

When you think about personalized cancer care, those annoying fruit flies in your kitchen are likely not the first things that come to mind. But they are exactly what My Personal Therapeutics uses to create personalized cancer treatment combinations.

September 30, 2019
·
9 min read
·
Chelsea Weidman Burke
Deals

Sweden’s Sobi to Acquire Dova Pharmaceuticals in $915 Million Deal

Shares of Dova Pharmaceuticals are up more than 38% in premarket trading after Sobi announced its intentions to acquire the company for $915 million.

September 30, 2019
·
2 min read
·
Alex Keown
Career Advice

How Life Sciences Professionals Can Find Jobs in the ‘Hidden’ Job Market

Do you know about the hidden job market and how to tap into it to find jobs? For years, career gurus have claimed that 75-95% of job vacancies are “hidden” in that they are not advertised or publicized.

September 30, 2019
·
4 min read
·
Katharine Hansen, PhD
Novigenix’s New Early Colon Cancer Detection Blood Test Demonstrates Positive Results

Novigenix SA announced promising data from a study of a new Immuno-Transcriptomic signature for early detection of colorectal cancer (CRC) in blood.

September 30, 2019
·
3 min read
Deals

Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology

Swedish Orphan Biovitrum AB announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. by means of a tender offer.

September 30, 2019
·
10 min read